|
04 Oct 2013 |
Isis Pharmaceuticals Advances Phase 2 Study of ISIS-SMN Rx in Infants With Spinal Muscular Atrophy
|
|
03 Oct 2013 |
Alnylam and Collaborators Publish Clinical Trial Results with ALN-PCS, an RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia, in The Lancet
|
|
02 Oct 2013 |
StemCells, Inc. Receives FDA Authorization of IND for Spinal Cord Injury
|
|
01 Oct 2013 |
Pluristem's PLX Cells Demonstrate Efficacy in Preclinical Study for Graft versus Host Disease
|
|
30 Sep 2013 |
Lion Biotechnologies Provides Update on Phase II Results for Metastatic Melanoma
|
|
30 Sep 2013 |
Alnylam Completes Enrollment of Phase II Clinical Trial and Initiates Open-Label Extension (OLE) Study with ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of Transthyretin-Mediated Amyloidosis (ATTR)
|
|
30 Sep 2013 |
Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
|
|
27 Sep 2013 |
Bioheart Announces Positive Preliminary Data From Phase I ANGEL Trial
|
|
25 Sep 2013 |
MOLOGEN AG submitted clinical trial application (IND) for MGN1703 to the FDA
|
